Forward-Looking Statements<\/strong><\/p>\nThis announcement may contain forward-looking statements. These statements are based on management\u2019s current estimates and expectations of future events as of the date of this announcement.\u00a0 Furthermore, the estimates are subject to several risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forward-looking statements.<\/p>\n
These risks and uncertainties include, but are not limited to, risks associated with the Company\u2019s ability to continue to operate as a going concern; the ability of the Company, its critical vendors, and key regulatory agencies to resume operational capabilities subsequent to the removal of COVID-19 pandemic restrictions; the Company\u2019s ability to raise sufficient additional funds to continue operations, including the successful closing of immediate short term financing, as well as any larger financing agreement and a delisting from the ASX; the Company\u2019s ability to execute STEP-1 under the FDA\u2019s Investigational Device Exemption; the Company\u2019s ability to enlist clinical trial sites and enroll patients in accordance with STEP-1; the risk that the FDA stops STEP-1 early as a result of the occurrence of certain safety events or does not approve an expansion of STEP-1; the Company\u2019s ability to enroll patients in accordance with I-STEP; the Company\u2019s ability to secure a CE Mark; the Company\u2019s ability to maintain compliance with its obligations under its existing convertible note and warrant agreements executed with Crystal Amber, including its obligations to make payment on the convertible note that is now due on 29 June 2020 and its ability to further restructure the terms of such convertible note with Crystal Amber if the Company is unable to raise sufficient funds to enable it to fully repay such convertible note when due; obtaining and maintaining regulatory approvals required to market and sell the Company\u2019s products; the possibility that future clinical trials will not be successful or confirm earlier results; the timing and costs of clinical trials; the timing of regulatory submissions; the timing, receipt and maintenance of regulatory approvals; the timing and amount of other expenses; the timing and extent of third-party reimbursement; intellectual-property risk; risks related to excess inventory; risks related to assumptions regarding the size of the available market; the benefits of the Company\u2019s products; product pricing; timing of product launches; future financial results; and other factors, including those described in the Company\u2019s filings with the SEC.<\/p>\n
Given these uncertainties, one should not place undue reliance on these forward-looking statements.\u00a0 The Company does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events or otherwise, unless it is required to do so by law.<\/p>\n
<\/p>\n
###<\/p>\n","protected":false},"excerpt":{"rendered":"
Update regarding the extension of the maturity date of the Senior Secured Convertible Promissory Note issued to Crystal Amber Fund Limited (\u201cCrystal Amber\u201d) on 15 June 2017 and associated matters.<\/p>\n","protected":false},"author":25,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-5989","post","type-post","status-publish","format-standard","hentry","category-pressemitteilungen"],"acf":[],"_links":{"self":[{"href":"https:\/\/eu.morphicmedical.com\/de\/wp-json\/wp\/v2\/posts\/5989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eu.morphicmedical.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eu.morphicmedical.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eu.morphicmedical.com\/de\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/eu.morphicmedical.com\/de\/wp-json\/wp\/v2\/comments?post=5989"}],"version-history":[{"count":0,"href":"https:\/\/eu.morphicmedical.com\/de\/wp-json\/wp\/v2\/posts\/5989\/revisions"}],"wp:attachment":[{"href":"https:\/\/eu.morphicmedical.com\/de\/wp-json\/wp\/v2\/media?parent=5989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eu.morphicmedical.com\/de\/wp-json\/wp\/v2\/categories?post=5989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eu.morphicmedical.com\/de\/wp-json\/wp\/v2\/tags?post=5989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}